BackMatinas Biopharma Holdings Overview

Matinas Biopharma Holdings Total Assets

Track Matinas Biopharma Holdings's total assets ($5.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$5.87M
51.19% YoYΔ $-6.16M vs prior year quarter

Peer average

Loading

Matinas Biopharma Holdings Total Assets History

Loading

Matinas Biopharma Holdings vs. peers: Total Assets Comparison

Loading

Matinas Biopharma Holdings Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Matinas Biopharma Holdings (MTNB) FAQ

The latest total assets for MTNB is $5.9M as of March 2026. That compares with $12M in the prior-year period — down 51.2% year over year. Investors often review this figure alongside Matinas Biopharma Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, MTNB's total assets moved from $12M to $5.9M — a 51.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Matinas Biopharma Holdings's operating scale or balance-sheet position.

A total assets figure of $5.9M for MTNB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MTNB's total assets ($5.9M), review year-over-year change from $12M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Matinas Biopharma Holdings's total assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.